About Us
Attomarker Ltd is a UK-based diagnostics company developing multiplex immune profiling technologies designed to support clinical decision-making in complex disease settings. Its diagnostics enable rapid, clinically relevant immune analysis from a single small blood sample and are designed for real-world clinical use.
Attomarker's Covid Antibody Spectrum Test holds a UKCA mark and is available through clinical partners. Additional Long Covid diagnostics are in development and the company has a pipeline in other immunological conditions.
Attomarker is a multi-award-winning spin-out from the research group of Professor Andrew Shaw at the University of Exeter, and its diagnostics are already in clinical use.
Press releases
Attomarker initiates Acceleration Round to scale immunology diagnostics
Exeter, United Kingdom, 8 February 2026 – Attomarker, a UK-based diagnostics company, has commenced an Acceleration Round to support the next... read more
08.02.2026 • By Attomarker Ltd
